1x 베팅 주소., Ltd.
1x 베팅 주소 Holdings Co., Ltd.

Tokyo, Japan, June 13, 2011 -- 1x 베팅 주소., Ltd. today announced the initiation of the phase I clinical trial of OCV-105 for pancreatic cancer in Japan. OCV-105 is a potential therapeutic cancer vaccine which has been co-developed by OncoTherapy Science, Inc. and Otsuka Pharmaceutical.

OCV-105 is a therapeutic cancer vaccine targeting the tumor specific antigen which is highly expressed w1x 베팅 주소h high frequency for pancreatic cancer. 1x 베팅 주소 is expected that OCV-105 suppresses the growth and progress of pancreatic cancer by the induction and activation of cytotoxic T-cells which directly damage pancreatic cancer cells.
The phase I clinical trial will evaluate the safety of OCV-105 in patients w1x 베팅 주소h pancreatic cancer refractory to or intolerance to the standard therapy.

Based on its corporate philosophy of 'Otsuka-people creating new products for better health worldwide,' 1x 베팅 주소 is dedicated to contributing to the health of people around the world.